Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 1494 818 026 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
+44 1494 818 026

Having recently found my self in need of the services of a recruitment agency, I registered with most of the usual suspects.
John , 2013

Merck Sharpe and Dohme and Codexis agree production alliance

4 April 2012 00:00 in Pharmaceutical Company Product News

Merck Sharpe and Dohme has announced a new alliance with Codexis that will lead to the development of an enzyme-based production method for the drug boceprevir.

Collaborative research conducted by staff from both companies will aim to create a highly efficient means of manufacturing a key intermediate in the production of boceprevir, the active ingredient in Merck's drug Victrelis.

Codexis' directed evolution technology CodeEvolver has been used to create the new custom enzyme or biocatalyst, which can increase chemical intermediate yield by 150 percent compared to the previous process.

This will help to reduce the costs involved in the commercial-scale production of the treatment, with the enzymatic method also offering benefits in terms of biodegradability and renewability.

Dr Richard Tillyer, senior vice-president for discovery and preclinical sciences at Merck Research Laboratories, said: "Incorporation of innovative environmentally sustainable means of manufacture is a key aspect of our research and development strategy."

This comes after Victrelis received a recommendation from the UK's National Institute for Health and Clinical Excellence last month as a therapy for chronic hepatitis C.ADNFCR-8000103-ID-801333589-ADNFCR

Other news stories from 04/04/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd